SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 19, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

August 8, 2022

Conditions
Coronary Artery DiseaseAtherosclerosisStent Placement
Interventions
DRUG

Dual Antiplatelet (DAPT) Therapy

"DAPT - one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient) with Aspirin.~Aspirin loading dose (LD) = 325 mg. Aspirin maintenance dose (MD) = 81 mg.~P2Y12 Inhibitor Loading Dose (investigator preference):~Clopidogrel 600 mg PO x 1 or 75 mg PO daily x 4; Prasugrel 60 mg PO x 1; Ticagrelor 180 mg PO x 1.~P2Y12 Inhibitor Maintenance Dose (investigator preference):~Clopidogrel 75 mg PO daily; Prasugrel 10 mg PO daily; Ticagrelor 90 mg PO BID."

DEVICE

The Synergy® stent

IVUS guided stent

Trial Locations (3)

10075

Northwell Hospital Systems, New York

85258

HonorHealth Research Institute, Scottsdale

02114

Massachusetts General Hospital, Corrigan Minehan Heart Center, Boston

All Listed Sponsors
collaborator

Boston Scientific Corporation

INDUSTRY

lead

HonorHealth Research Institute

OTHER